The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Positive Start.
Meddler, if I had one share pick for next year it would be Ixi.
Great management, new contracts, plenty of cash and lots of potential.
I am very happy to be locked and loaded.
Atb.
Could be the star riser of the coming year.
Excellent point LagerKhan. Loving the username too.
Should be a very interesting lead up to end of year.
Crazy price, £10.3 million market cap and £7.9 million cash.
Future underpinned by £15 million of new contracts, as per the results statement.
Patience required.
Great RNS. Big contract wins.
This is a multi/bagger in the making....Clazas......hold on to your hats and come on board imho...cheap now ....won’t be once Zak mir charts this to 50p + DYOR
I think, because of the tiny freefloat and the lack of rampers (due to no placing, CLN's, warrants to flip), the market has completely missed the stunning news this morning.
Thanks to the freefloat, however, any buying whatsoever will send this back to 40p, as it hit in September before these excellent results.
So what's occurring here, this imo looks wonderful?
IXICO CEO Giulio Cerroni on record revenues and significant contract extension
Share
09:48 04 Dec 2018
Giulio Cerroni, chief executive of IXICO PLC (LON:IXI), caught up with Proactive London's Andrew Scott to discuss their results for the year to the end of September as well as the expansion to a contract.
The scope of a current contract with a top 10 biopharmaceutical company has been enlarged, increasing the value by US$2.4mln over the remaining six-year term of the agreement to US$5.1mln.
Where IXICO's results are concerned revenue rose 32% to £5.39mln from £4.10mln the year before, while the gross margin improved to 58.8% from 56.4%.
The loss before tax narrowed to £793,000 from £1.91mln the previous year.
Great to see this kind of number...this is just the beginning
Ahh.
Not sure if SCAP do broker notes (although they ought to do something for their £)
You'd think someone like Miton would be all over this.
Has not had one for a few years
What was the last target?
I would expect broker upgrade to target £1.00 +
Ixico jumps as new contract wins help to slash losses
Tue, 4th Dec 2018 08:21
(Sharecast News) - Data analytics outfit Ixico leapt on Tuesday after narrowing its full-year loss and increasing revenue by securing £15m of new and expanded multi-year client contracts.
For the year ended 30 September Ixico, which assists pharmaceutical companies with analysis of data from brain scans and other procedures, achieved revenue at actual exchange rates of £5.4m, an increase of 32% over the prior year, thus reducing its loss before tax and operating loss from £1.9m to £0.8m across the same time frame.
With £15m of new and expanded multi-year client contracts won the company achieved record revenue in its core imaging business.
Ixico cited increased project volumes, improved productivity and cost control as the drivers behind a reduced EBITDA loss of £0.6m, down from £1.4m, while gross margins increased to 58.8% from 56.4%.
Chief executive Giulio Cerroni said: "2018 has been another year of significant progress in which we have delivered on our financial commitments, whilst continuing to invest in the long-term future of the company. We have reported record revenues with underlying growth of 41%, further improved gross profit performance and reduced operating losses."
Cash and cash equivalents at the year-end stood at £7.9m, up from £2.4m at the same point the year before, after the company completed a placing of £5.5m and achieved neutral operating cash flows.
Ixico said in a statement that the funds from the placing will be used to invest in people, products, processes and IT infrastructure needed to further accelerate its commercially-led growth strategy.
"With a successful capital placing to invest in new market and product development, we go into the new financial year with increased commercial traction, ambitious growth plans and a strengthened organisation focused on delivering technology-driven data analytics to our global biopharmaceutical clients," said Cerroni.
The AIM-traded company continued the good momentum post-year-end, with the extension of a contract with a top 10 pharmaceutical giant, which has increased in value from $2.7m to $5.1m over a six-year period to cover a significantly higher number of patients at various international study sites. Ixico uses technology to help select include patients for clinical trials and to assess the safety and efficacy of new drugs in development.
Perfect. Thank you, TLK.
Stunning results this morning. Would love to know who the big pharma is.
12.1 million freefloat? Is that it? No wonder this is so far under the radar.
All that glitters.
Delighted with results.
Growth due to new contracts and expansion of existing contracts.
First year of revenue from wearables.
Partnership with Biogen going well on MS drug.
Bringing in new talent and promoting from within.
Cash in bank 7.9 million, cash burn for year 100k.
Staff revenue per head increased from 55k to 95k.
Raising profile of the company and focusing on Data Analytics.
Collaborations with Academia on Artificial Intelligence, Kings College mentioned.
Hope this helps.
Could anyone summarise what was said in interview?
Can't watch currently.
Cheers.
Welcome aboard all that glitters
Sorry Smith, not very good with links, just go on to proactiveinvestors co uk and click on videos, sure you will enjoy it.
I'm in for a whopping 16k :oD
Looks good. Not a high volume shares, but tempt people out of HVO perhaps.
Are you able to post the link
Very good interview on Proactive Investors, worth a watch.
Lots 5o look forward to.